%D8%B1%D9%8A%D8%AA%D9%88%D9%83%D8%B3%D9%8A%D9%85%D8%A7%D8%A8%D8%B1%DB%8C%D8%AA%D9%88%DA%A9%D8%B3%DB%8C%E2%80%8C%D9%85%D8%A8Category:RituximabRituximabRituximabRituximabRituximab%D8%B1%DB%8C%D8%AA%D9%88%DA%A9%D8%B3%DB%8C%E2%80%8C%D9%85%D8%A8RituksimabiRituximab%D7%A8%D7%99%D7%98%D7%95%D7%A7%D7%A1%D7%99%D7%9E%D7%90%D7%91Rituximab%D5%8C%D5%AB%D5%BF%D5%B8%D6%82%D6%84%D5%BD%D5%AB%D5%B4%D5%A1%D5%A2RituximabRituximab%E3%83%AA%E3%83%84%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96%D0%A0%D0%B8%D1%82%D1%83%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1RituximabRituximab%E0%AC%B0%E0%AC%BF%E0%AC%9F%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AC%BF%E0%AC%AE%E0%AC%BE%E0%AC%ACRytuksymabRituximab%D0%A0%D0%B8%D1%82%D1%83%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1RituksimabRituksimabRituksimabRituximab%D0%A0%D0%B8%D1%82%D1%83%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1RituximabQ412323%E5%88%A9%E5%A6%A5%E6%98%94%E5%96%AE%E6%8A%97
about
sameAs
bullous pemphigoidchronic lymphocytic leukemiaIgG4-related diseasenon-Hodgkin lymphomainterstitial lung diseasegraft-versus-host diseasecentral nervous system lymphomathrombotic thrombocytopenic purpuraPost-transplant lymphoproliferative disorderlupus nephritisarthritismembranous glomerulonephritisWaldenström's macroglobulinemiacryoglobulinemiaMicroscopic polyangiitisCastleman's diseasehairy cell leukemialymphomadiffuse large B-cell lymphomamantle cell lymphomaautoimmune hemolytic anemialeukemiaB-cell lymphomanephrotic syndromethrombocytopenianeuromyelitis opticamultiple sclerosismyasthenia gravisprimary angiitis of the central nervous systempolymyositis
P2176
P3781
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionCombination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaResponse to Influenza Vaccination in Lymphoma Patients Treated With RituximabSequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaClinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaMLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaPhase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell LymphomaEfficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell LymphomaEfficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaDA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsBendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaLow-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaA Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid ArthritisMetronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasOptimizing HBV Management During Anti-CD20 AntibodiesEfficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune ThrombocytopeniaTransplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse LymphomRituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic LeukemiaAllogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal TransplantationPhase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaRituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaA Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaEL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaA Phase I/II Trial of VR-CHOP in Lymphoma PatientsRituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaEvaluation of the Safety and Efficacy of Nipent, Cytoxan, and RituxanPhase II Trial of Pentostatin and Targeted BusulfanZevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasIbritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent LymphomasBortezomib and Rituximab for Patients With Waldenstrom's MacroglobulinemiaPhase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCLA Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell LymphomaRituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic PurpuraCHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone LymphomaOxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLAn Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only
P4844
Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.Acquired Hemophilia A Presenting as Intramuscular HematomaRituximab treatment for isolated IgG4-related hypophysitis in a teenage femaleEfficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemiaRadiotherapy in advanced glottic laryngeal carcinoma in a patient with Wegener's granulomatosis: how much radiation dose is needed?High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patientsEfficacy of rituximab in resistant palindromic rheumatism: first report in literatureIndolent primary effusion lymphoma-like lymphoma in the pericardium: A case report and review of the literatureRituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature reviewAdvances in autoimmune myasthenia gravis managementPrimary hepatic marginal zone lymphoma: A rare coincidenceEffectiveness of rituximab in neuromyelitis optica: a meta-analysisImmunosuppressive therapy with rituximab in common variable immunodeficiencyOutcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 PatientsRituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialHigh-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from ChinaRare presentation of disseminated follicular lymphoma as an ill-defined reticular patch over the scalp and foreheadHow the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomasFollicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximabClinical efficacy and safety of rituximab in lupus nephritisThe Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based StudySystematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphomaR-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDYWomen with Diffuse Large B Cell Lymphoma Benefit More from Rituximab-Containing ChemotherapyTherapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpuraPrimary testicular lymphoma: A SEER analysis of 1,169 casesBendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False NegativesHCV-Associated Nephropathies in the Era of Direct Acting Antiviral AgentsInflammatory activity and vitamin D levels in an MS population treated with rituximabPediatric anti-NMDA receptor encephalitis with catatonia: treatment with electroconvulsive therapyCD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope SpreadingRituximab Use in the Management of Childhood Nephrotic SyndromeTrends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysisMutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeuticsThymectomy may not be associated with clinical improvement in MuSK myasthenia gravisImpact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation (2008-10-31)Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaPembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
P921
Q1004647-22B8565B-01E2-457C-99CD-FC1EBC0B313CQ1088156-7879E283-5E9B-450F-9349-E133B964DDA0Q11039483-2d196be6-48cc-a225-e3e4-bb7b8111ee98Q1138590-E67BB9B0-0ADB-4360-B8F8-E3D84CC0A244Q1153419-35B92EA2-69BC-4F17-935E-086B2525045CQ1194520-B3E428C2-6433-47C5-82D8-8B0000BF49F0Q136312-D1BA1ED5-F906-4CA9-9DEF-EDE452A5DF65Q1426491-FA25C03E-B550-492C-A91C-958DD1024DABQ1594599-6B691A2C-5E89-40DC-AA71-5822E007B5CCQ1621830-FDC3A59B-77F5-48F2-97EF-C4D3013401E5Q170990-8C2DBE7F-748E-41BA-BADF-64BA836816A7Q1713037-5951EC2F-B8C7-422D-8C0E-E773A5E41D1DQ1778287-A375D6C3-0F80-45BD-9A52-7A173C303A33Q1790371-21E74A2A-2E73-4B54-91D4-2B233B39FDA0Q1934069-2B4E6020-397A-44B9-9F90-CA5752D80BB1Q1947302-EDCABD0E-0505-4F90-B627-8DC32846EC1FQ201299-305FACBD-DE72-4314-B47E-AE9D05F62B59Q208414-8ADBF828-B825-4E4E-BF21-1170D03690EFQ2626074-A8DC65BB-9114-4AE5-B8AA-0B7E1A5760AAQ268713-3A1AC89C-B205-41EA-8CF9-A849B5AA266EQ28814-21B883B4-6672-43A2-A3B9-EB5E3DE27EC1Q29496-C1821EC2-109A-43D7-86D0-2D692B099A0FQ4833719-D36474B7-AC82-4DF5-AEEC-C0A22A004136Q504790-96A912A6-2F76-4E6D-827F-40A0D9227137Q585285-E9C48B3A-1287-410A-9918-E2BE89B853D8Q611458-D9E13397-DBD9-4A68-8A73-86E9C37B06CCQ8277-B9DA173B-860E-4DCB-99DF-6E6065CB2E7FQ8285-32B0B069-C21F-4934-A01C-B7F863F002F5Q93333268-069eac38-46bb-15cf-b184-868ee51252e1Q980926-4E6BE503-821F-4E49-8BB6-C768E006809A
P2176
Q61694878-F4D9E34E-C1E3-44B9-B9B0-950A31538D75Q61694890-6E6403D7-F5BD-400F-9E4C-79EE99BD6F49Q61707484-0C0927C6-C3F0-41EA-843E-6F9A5BF87D59Q61862224-920823E5-8A1C-47CF-A901-7D7AE2188AFDQ61864700-1433FC28-9616-4B27-88C9-919E85A504B3Q61864899-9E0AD4AC-7A24-48A3-B2E6-C60C3CDE6536Q61865034-3FC4C4A2-F711-4B35-B946-2420C5B3A43FQ61894581-997098A7-5D6C-47A5-B414-7ABF76B07B2EQ61902398-81467EE5-7925-4E92-9860-7F640D405F5AQ61902642-30568B28-FD8C-400B-A14E-00DDBA9C9C82Q61902671-41A0216C-23FF-41ED-AC7C-F2CAD4225BC6Q61904952-4304934D-6CAD-4DCC-A8CF-4FA4E97E4CC6Q61906943-D5635B26-7F76-4088-B53D-621707F7BBBFQ61907867-37328D6F-CCAD-42A9-BF15-1B2598E9669BQ61909197-0F603993-B67B-4B45-B90A-9AA4B0F26289Q61909217-34F79B5B-E4D8-4F59-8404-0D05AE7BCF67Q61909621-20A25BC0-AA47-4DDB-B28F-D3DB0491374DQ61909747-40A8359C-5B4F-42C3-A5F3-B0158175E913Q61914315-72CF4D2D-F2DD-4016-8A13-56A4DC1A45D6Q61914412-975B9006-BA44-4D27-A878-0913CDEFAE25Q61914538-1B7E7315-57C8-4508-9D45-D2E7004D6BF3Q61914708-CA4C49F0-3FE3-4DDE-A8D5-5AEEA4FCCBADQ61914857-EAB4427F-018C-4541-90EA-55CB9D04E148Q61915196-D1C63736-8A24-4644-B450-27860662D0E5Q61915294-124E3C1A-C403-4B26-BB2D-76969A874DE6Q61915350-A8BEA49A-07A4-446A-BD7C-C33ED7E758CBQ61915537-62AEF9FA-0846-4C9F-B741-77C1491DFCAAQ61915589-A2A57050-5AF8-436A-98DD-435BFFA87E02Q61917454-DE5F5A91-DA4C-4624-8387-B3E836391523Q61917495-8E8D9826-7E79-4BD7-A3A1-DFB98A6C164EQ61917800-80A3CB6E-CAF1-4706-9A2C-3F293A677733Q61917801-CBCA6C79-D5BC-41AD-973E-A849999FD4CFQ61917916-9BA19702-5B7D-4BDB-ABBB-3327D3148936Q61918051-CC1FA414-4557-4C37-9DAC-9B25D8AD8B38Q61918397-AC2577DD-C825-4E3A-9EEE-A2C7EB2823D2Q61918427-4ABF81E5-06D5-43E1-AA55-F3D7505D094BQ61920594-FE8706B6-2D14-4961-A408-07A7B6AB2162Q61920823-6E9DADF5-BFE4-42DA-8D5A-41EE40B15BD2Q61920880-AE5D1333-E327-4727-858F-7126534CA81BQ61920983-2AD85A50-D48D-45FA-A25C-6E9952AB60BA
P4844
Q55508861-64E99380-9397-4925-88DA-D97AE8AAD3F5Q60046180-8023ABD5-8156-4BE3-87CE-04384CBC1812Q60927462-25651BE1-2CC4-4816-BB2F-208DB74245D3Q60957798-E78F8F4E-7EAE-4483-B513-88666165CBBBQ61807320-ABD4C023-AC0B-47FA-BA60-82FF088F0122Q61811268-D2BA8CE2-1941-4204-A7A3-E6A07802801CQ61811965-662612A1-8DC3-4EC3-84EB-9EC0B17B0EEDQ64039331-15BB21A6-5F2C-47E4-96B5-FBF01D3D9828Q64039339-89C2D8E1-94C2-4660-BE3F-635F65368CBCQ64042522-3094BC41-7C0B-4D8B-BBAF-9840268DEB62Q64044796-42A662BC-F8CA-4028-8AAE-84BF9C07E07BQ64046105-0F9C9181-F02A-43AB-BBE5-4BECDF8E86B0Q64055711-C9CBC14F-B695-4737-BB23-EF4DA94B4A5AQ64065293-DC01390E-5D5C-40E6-AEC9-DCC76F8148CDQ64072166-88584AF8-7AD2-47AE-B677-FD45BEAEE398Q64074212-3B5706E8-F6BF-4DE7-8F0A-612D63C32C9CQ64075328-5778E1D2-F260-4CC4-A973-7DC368A228D1Q64085783-C7E48FB2-48DF-4310-B59D-9E60CC23BEEAQ64095781-78C33415-AB8F-4A6D-8E0D-027B7ABB844EQ64103696-9B06EB7E-F211-40B1-BD42-17C743F2E3A4Q64106958-CD916605-1BCA-4335-856E-77391B84AB91Q64114443-46442DB9-48AB-4D26-93F5-51232E6EBE4FQ64122816-08C2A813-CEC8-4420-BF42-57DF134D541DQ64123976-858EEDD2-B8F8-4369-A441-86131FB9C93FQ64124092-C2517489-AD77-4FD8-99BA-46834D37FCC1Q64233375-8DD8ED73-6E20-44EB-A382-95C7C578E9BDQ64234052-6057DDFF-96D2-4F99-ADC0-AEC984778D66Q64240346-26AA6166-D6FF-4981-9867-3B0C197E2E9EQ64244966-2FDB8558-A060-4C0E-B359-F5A5A8A195C9Q64249921-14EF70A8-2C1B-46A8-A238-5F7517DB4204Q64250342-867EA471-7112-462B-AA1B-6CFAD5471DE5Q64253321-7F50407A-E962-4477-B7A5-A99B584FBDFBQ64264101-33DA6BB5-158D-4047-BB9B-EB998D58E750Q64280041-D44693C0-4CBB-4254-87B3-783CC3887379Q64296645-20ADD502-5FB6-404B-B209-DFA782C32F39Q66724826-2C93AAFA-6A28-4BD5-8EEE-F53C063C9CF7Q86170561-5C4432CE-339F-46C9-B082-37323D1B81B7Q86254246-C1755A3E-6F48-4075-BB96-932D93AAC5C8Q86271504-69E6975A-6D6D-4984-B3A4-45746C271DE2Q86308033-97646F16-71CC-451A-8909-FEC6449C35D5
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Rituksimab
@sh
Rituksimab
@sl
Rituksimabi
@fi
Rituximab
@de
Rituximab
@hu
Rituximab
@id
Rituximab
@nb
Rituximab
@nl
Rituximab
@sv
Rituximab
@vi
type
label
Rituksimab
@sh
Rituksimab
@sl
Rituksimabi
@fi
Rituximab
@de
Rituximab
@hu
Rituximab
@id
Rituximab
@nb
Rituximab
@nl
Rituximab
@sv
Rituximab
@vi
altLabel
174722-31-7
@fr
AntiCD20
@en
C6416H9874N1688O1987S44
@fr
C6416H9874N1688O1987S44
@it
IDEC-102
@en
IDEC-C2B8
@en
Ig gamma-1 chain C region
@en
MabThera
@de
MabThera
@sl
Mabthera Rituxan
@en
prefLabel
Rituksimab
@sh
Rituksimab
@sl
Rituksimabi
@fi
Rituximab
@de
Rituximab
@hu
Rituximab
@id
Rituximab
@nb
Rituximab
@nl
Rituximab
@sv
Rituximab
@vi
P2175
P2868
P31
P672
P486
P592
P6366
P646
P665
P672
P2115
N0000148560
P2175
P2275
Rituximab
@en
P231
174722-31-7
P232
P2566
100.224.382
P267
P274
C6416H9874N1688O1987S44